Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$126.4MCash on Hand
34.2mo Cash Runway
Follow EPRX by emailGet an email when EPRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about EPRX, unsubscribe in one click. Privacy
📣 What EPRX Says Is Next
in December · ““We remain on track to report interim results from the Phase 2b portion of the RESOLVE trial in December, and were pleased to announce in mid-October that we had reached our target enrollment of 120 patients,” said Dr. James A.”
Company press release, Nov 10, 2026 · SEC filing
in December 2026 · EP-104GI: “The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026.”
Company press release, Nov 10, 2026 · SEC filing
coming months · “Eupraxia plans to disclose additional data from the open-label Phase 1b/2a portion of the RESOLVE trial in the coming months.”
Company press release, Nov 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Earnings Q3 2026 net loss of $15.2 million versus $6.4 million a year earlier, driven by doubled RESOLVE Phase 2b trial costs. Cash and equivalents of $75.2 million plus $51.2 million short-term investments, with runway into 2H 2028. Phase 2b interim data expected December 2026. Form 6-K · SEC filing · Press release
Nov 10, 2026 ·
Financing Eupraxia set up an at-the-market program with Jefferies to sell up to US$125 million of common shares. The CFO said the company has no current plan to use it in the near term and that cash covers planned expenses until H2 2028. Form 6-K · SEC filing · Press release
Nov 10, 2026 ·
Financing Filed an Open Market Sale Agreement dated November 10, 2026 with Jefferies LLC and Jefferies Securities, Inc. for at-the-market sales of common shares. The agents receive a 3.0% selling commission, and the Company may set a floor price of at least US$1.00. Offering amounts are not stated in the excerpt. Form 6-K · SEC filing · Press release
Oct 22, 2026 ·
Eupraxia will present at the Craig Hallum Biotech Catalyst Virtual Conference on October 22, 2026, BIO-Europe, the Stifel 2026 Healthcare Conference, and the Jefferies Global Healthcare Conference in London. It will also host a virtual Analyst Day on EP-104GI for eosinophilic esophagitis on November 13, 2026. Form 6-K · SEC filing · Press release
Oct 15, 2026 ·
Clinical trial Reached its 120-patient enrollment target on October 12, 2026 in the placebo-controlled Phase 2b portion of the RESOLVE trial of EP-104GI for eosinophilic esophagitis. Over 3,000 injections given with no treatment-related serious adverse events; interim Phase 2b analysis expected December 2026. Form 6-K · SEC filing · Press release
Oct 9, 2026 ·
Clinical trial Eupraxia will present three abstracts from its ongoing Phase 1b/2 RESOLVE trial of EP-104GI in eosinophilic esophagitis at the ACG 2026 meeting (Oct 12, Nashville) and UEG Week 2026 (Oct 18-19, Barcelona). Interim Phase 2b data are expected in December 2026. Form 6-K · SEC filing · Press release
Sep 30, 2026 ·
Clinical trial Reported 52-week data from the highest dose cohort of EP-104GI in the Phase 1b/2a RESOLVE trial for eosinophilic esophagitis. Clinical remission at 52 weeks was 64% (9 of 14 patients) across cohorts 5-9, with no treatment-related serious adverse events reported. Phase 2b interim data are expected in December 2026. Form 6-K · SEC filing · Press release
Sep 8, 2026 ·
Listing Eupraxia's common shares have begun trading on the Nasdaq Global Select Market, its highest tier, under the same ticker EPRX, with no shareholder action required. Management will present or meet investors at the Cantor, H.C. Wainwright and Morgan Stanley conferences in September 2026. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 1/2 · Recruiting · A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
EPRX holds $126.4M in cash and short-term investments and burns about $11.1M/quarter from operations,
an estimated runway of 34.2 months at that rate (BioRadar estimate, not company guidance).
Share count 35,641,603 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full EPRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EPRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.